Breakthrough Gene Therapy Achieves Complete Remission in Previously Untreatable Cancers

A phase three clinical trial of a personalised CAR-T cell therapy has reported complete remission rates of 84 percent across four types of cancer previously considered incurable — described by oncologists as a potential turning point in cancer treatment.

The approach overcomes previous limitations in solid tumour treatment through innovations in T-cell engineering, a modified delivery mechanism, and modified immune suppression during treatment.

“We are seeing complete remission in patients who had exhausted every available treatment option,” said the lead oncologist. “Some are now disease-free two years post-treatment.”